Business
GeoVax Comments on U.S. America First Global Health Strategy and Highlights Company's Role in Advancing American Innovation, Pandemic Preparedness, and Global Health Security
Pipeline Intersects With the Vast Majority of Strategic Initiatives to Make America Safer, Stronger, and More Prosperous ATLANTA, GA - September 29, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company develo...
About this update from Geovax Labs, Inc.
[{"type":"image","caption":"","headline":"GeoVax Highlights 2026 as a Pivotal Year for Progress","size":{"original":{"width":140,"height":140,"url":"https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CK3y_RQaAtNDQGf8lPQXOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc","width":140,"height":140}}},{"type":"text","content":"Pipeline Intersects With the Vast Majority of Strategic Initiatives to Make America Safer, Stronger, and More Prosperous","length":120,"tagName":"p"},{"type":"text","content":"ATLANTA, GA - September 29, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies against infectious diseases and cancers, today announced its strong support for the newly unveiled America First Global Health Strategy by U.S. Secretary of State Marco Rubio. The strategy underscores the importance of American innovation, domestic pharmaceutical manufacturing, and global partnerships in strengthening health security and safeguarding U.S. national interests.","length":554,"tagName":"p"},{"type":"text","content":"GeoVax's pipeline, including its Mpox/Smallpox vaccine (GEO-MVA), next-generation multi-antigen COVID-19 vaccine (GEO-CM04S1), and other infectious disease vaccines in development directly aligns with the policy's pillars of making America safer, stronger, and more prosperous.","length":285,"tagName":"p"},{"type":"text","content":"Advancing Pandemic Preparedness","length":31,"tagName":"p"},{"type":"text","content":"The new strategy highlights the urgent need for rapid outbreak detection and deployment of medical countermeasures. GeoVax is rapidly developing a continuous cell-line (AGE1) manufacturing technology which will enhance scalability, speed, and resilience - addressing longstanding supply chain vulnerabilities in U.S. biodefense. Utilizing this advanced manufacturing process, GeoVax's MVA-based platform is uniquely suited for rapid vaccine response against infectious disease threats including Mpox, smallpox, Zika, and hemorrhagic fever viruses.","length":551,"tagName":"p"},{"type":"text","content":"GeoVax is also committed to developing regional supply capabilities to ensure timely and ...